The aim of this project, which was commissioned by NICE through the NIHR HTA Programme as part of the NICE’s Single Technology Appraisal process, was to review the evidence for the clinical and cost-effectiveness of Aflibercept for the treatment of adults suffering from wet age-related macular degeneration (wet AMD). The clinical evidence submitted by the company (Bayer Pharma AG) responsible for manufacturing Aflibercept (Eylea) consisted of two RCTs comparing Aflibercept with ranibizumab and 10 RCTs involving either Aflibercept or ranibizumab. Aflibercept proved to be a safe and cost-effectiveness option for the treatment of wet AMD in adults. The Aberdeen HTA Group acted as the Evidence Review Group (ERG) for the project and provided an independent critique of the clinical and cost-effectiveness evidence submitted by the company.
After taking into consideration the company submission and the findings of the ERG’s critique, NICE released a technology appraisal guidance (TA294, July 2013). Aflibercept is currently recommended by NICE as an option for treating wet age related macular degeneration only if i) Aflibercept is used in accordance with the recommendations for ranibizumab in and, ii) the manufacturer provides Aflibercept in line with the commercial access agreement with NHS England.
Miriam Brazzelli; email@example.com
Cummins, E, Fielding, S, Johnston, R, Rothnie, K, Stewart, F, Lois, N, Burr, J, Brazzelli, M. Aflibercept solution for injection for the treatment of wet age-related macular degeneration. Evidence Review Group report in support of NICE STA Programme. University of Aberdeen: Health Services Research Unit; 2013 URL: https://www.nice.org.uk/guidance/ta294/documents/macular-degeneration-wet-agerelated-aflibercept-1st-line-evaluation-report2